Estradiol protects the cochlea against gentamicin ototoxicity through inhibition of the JNK pathway

Mariko Nakamagoe1, Keiji Tabuchi, Isao Uemaetomari

  • 1Department of Otolaryngology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.

Hearing Research
|January 16, 2010
PubMed

Insights

17beta-Estradiol (E2) protects against gentamicin-induced outer hair cell death by inhibiting apoptosis. This estrogen treatment reduced cell loss and key apoptotic markers like c-jun N-terminal kinase (JNK) activation.

Area of Science:

  • Ototoxicity research
  • Cell biology
  • Endocrinology

Background:

  • Gentamicin is an ototoxic antibiotic causing outer hair cell (OHC) death via apoptosis.
  • C-jun N-terminal kinase (JNK) and caspases are key mediators of this apoptotic pathway.
  • 17beta-Estradiol (E2) exhibits antiapoptotic properties in various cell types.

Purpose of the Study:

  • To investigate the protective effects of E2 against gentamicin-induced OHC apoptosis.
  • To determine if E2 modulates JNK activation and apoptotic markers in OHCs exposed to gentamicin.

Main Methods:

  • Organ of Corti explants from young rats were cultured and exposed to gentamicin.
  • Effects of E2 on OHC survival, JNK activation, and TUNEL staining were assessed.
  • Dose-dependent responses to E2 were evaluated.

Main Results:

  • E2 significantly reduced gentamicin-induced OHC loss in a dose-dependent manner.
  • E2 treatment decreased JNK activation and TUNEL-positive cells in gentamicin-exposed explants.
  • These findings suggest E2 inhibits the apoptotic cascade initiated by gentamicin.

Conclusions:

  • E2 confers protection against gentamicin-induced ototoxicity.
  • E2 acts by inhibiting JNK activation and downstream apoptotic pathways in OHCs.
  • E2 represents a potential therapeutic agent for preventing gentamicin-induced hearing loss.